NCT07093008

Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

A Phase 1, Investigator- and Participant-blinded, Placebo-Controlled, Randomized, Crossover Study to Assess the Relative Bioavailability of Two Formulations of AQ280 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: AQILION AB · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.

Conditions

• Eosinophilic Esophagitis

Interventions

Type	Name	Description
DRUG	AQ280 Capsule	AQ280 administered orally in capsule formulation.
DRUG	AQ280 Tablet for Oral Suspension	AQ280 administered orally in tablet for oral suspension formulation.
DRUG	Placebo Capsule	Placebo administered orally in capsule formulation.
DRUG	Placebo Tablet for Oral Suspension	Placebo administered orally in tablet for oral suspension formulation.

Timeline

• Start date: 2025-06-13
• Primary completion: 2025-07-16
• Completion: 2025-07-22
• First posted: 2025-07-30
• Last updated: 2025-08-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study